Showing results (61-70 of 102) with videos related to
Sort By:
Pageof 11
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2013
Differential effect of soy isoflavones in enhancing high intensity radiotherapy and protecting lung tissue in a pre-clinical model of lung carcinomaGilda G Hillman, Vinita Singh-Gupta, David J Hoogstra, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 18, 2020
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX StudyTony Mok, Solange Peters, D Ross Camidge, et al.Lung Cancer (Auckland, N.Z.)|February 4, 2020
Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 StudiesShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 1, 2013
Radioprotection of lung tissue by soy isoflavonesGilda G Hillman, Vinita Singh-Gupta, Fulvio Lonardo, et al.ESMO Open|July 19, 2018
Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancerSai-Hong Ignatius Ou, Mark A Socinski, Shirish Gadgeel, et al.Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Emergence of FGFR3-TACC3 fusions as a potential by-pass resistance mechanism to EGFR tyrosine kinase inhibitors in EGFR mutated NSCLC patientsSai-Hong Ignatius Ou, Leora Horn, Marcelo Cruz, et al.British Journal of Cancer|November 18, 2017
Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLCShirish Gadgeel, Alice T Shaw, Fabrice Barlesi, et al.Clinical Lung Cancer|July 6, 2021
Comparison of SP142 and 22C3 Immunohistochemistry PD-L1 Assays for Clinical Efficacy of Atezolizumab in Non-Small Cell Lung Cancer: Results From the Randomized OAK TrialShirish Gadgeel, Fred R Hirsch, Keith Kerr, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 13, 2005
Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignanciesPatricia M Lorusso, Alex A Adjei, Mary Varterasian, et al.JTO Clinical and Research Reports|July 25, 2022
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLCDong-Wan Kim, Shirish Gadgeel, Scott N Gettinger, et al.Pageof 11